CELZ (Creative Medical Technology Holdings) Piotroski F-Score: 3 (As of Jun. 25, 2026) — 25% Below Median


CELZ Creative Medical Technology Holdings Inc CELZ
36 GF Score
Price $2.00
GF Value $0.32
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Creative Medical Technology Holdings Piotroski F-Score?

Creative Medical Technology Holdings CELZ 36 Piotroski F-Score is 3 as of Jun. 25, 2026, which is 25% below its 10-year median of 4.00. GuruFocus rates CELZ with a GF Scoreâ„¢ of 36/100 and a GF Valueâ„¢ of $0.32 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,342 Biotechnology companies, Creative Medical Technology Holdings ranks better than 55.14% on this metric.

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Creative Medical Technology Holdings has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Creative Medical Technology Holdings's Piotroski F-Score or its related term are showing as below:

CELZ' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 7
Current: 3

During the past 13 years, the highest Piotroski F-Score of Creative Medical Technology Holdings was 7. The lowest was 2. And the median was 4.

Creative Medical Technology Holdings  (NAS:CELZ) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Creative Medical Technology Holdings Piotroski F-Score Related Terms


Creative Medical Technology Holdings Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Creative Medical Technology Holdings's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Creative Medical Technology Holdings Piotroski F-Score Chart

Creative Medical Technology Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 3.00 4.00 3.00 4.00

Creative Medical Technology Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.00 4.00 4.00 3.00

CELZ vs APM, BCLI, GNPX: Piotroski F-Score Comparison

For the Biotechnology subindustry, Creative Medical Technology Holdings's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Creative Medical Technology Holdings Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Creative Medical Technology Holdings's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Creative Medical Technology Holdings's Piotroski F-Score falls into.


CELZ
36GF Score
Creative Medical Technology Holdings Inc CELZ
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -1.233 + -1.236 + -1.888 + -1.405 = $-5.76 Mil.
Cash Flow from Operations was -1.159 + -1.169 + -1.938 + -1.323 = $-5.59 Mil.
Revenue was 0 + 0 + 0.003 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0.002 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(8.347 + 7.105 + 5.853 + 7.81 + 6.441) / 5 = $7.1112 Mil.
Total Assets at the begining of this year (Mar25) was $8.35 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $6.06 Mil.
Total Current Liabilities was $0.31 Mil.
Net Income was -1.558 + -1.04 + -1.854 + -1.638 = $-6.09 Mil.

Revenue was 0.008 + 0 + 0.003 + 0.003 = $0.01 Mil.
Gross Profit was 0.005 + 0 + 0.002 + 0.002 = $0.01 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(9.62 + 7.99 + 6.888 + 6.669 + 8.347) / 5 = $7.9028 Mil.
Total Assets at the begining of last year (Mar24) was $9.62 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $7.84 Mil.
Total Current Liabilities was $0.29 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Creative Medical Technology Holdings's current Net Income (TTM) was -5.76. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Creative Medical Technology Holdings's current Cash Flow from Operations (TTM) was -5.59. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-5.762/8.347
=-0.6903079

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-6.09/9.62
=-0.63305613

Creative Medical Technology Holdings's return on assets of this year was -0.6903079. Creative Medical Technology Holdings's return on assets of last year was -0.63305613. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Creative Medical Technology Holdings's current Net Income (TTM) was -5.76. Creative Medical Technology Holdings's current Cash Flow from Operations (TTM) was -5.59. ==> -5.59 > -5.76 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0/7.1112
=0

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0/7.9028
=0

Creative Medical Technology Holdings's gearing of this year was 0. Creative Medical Technology Holdings's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=6.059/0.308
=19.67207792

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=7.844/0.286
=27.42657343

Creative Medical Technology Holdings's current ratio of this year was 19.67207792. Creative Medical Technology Holdings's current ratio of last year was 27.42657343. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Creative Medical Technology Holdings's number of shares in issue this year was 3.702. Creative Medical Technology Holdings's number of shares in issue last year was 1.981. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.002/0.003
=0.66666667

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.009/0.014
=0.64285714

Creative Medical Technology Holdings's gross margin of this year was 0.66666667. Creative Medical Technology Holdings's gross margin of last year was 0.64285714. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=0.003/8.347
=0.00035941

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=0.014/9.62
=0.0014553

Creative Medical Technology Holdings's asset turnover of this year was 0.00035941. Creative Medical Technology Holdings's asset turnover of last year was 0.0014553. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+0+1+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Creative Medical Technology Holdings has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 3 mean?
Creative Medical Technology Holdings (CELZ) has a Piotroski F-Score of 3 as of Jun. 25, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Creative Medical Technology Holdings and its competitors. This is 25% below median its historical median of 4.00. Over the past decade, Creative Medical Technology Holdings' Piotroski F-Score has ranged from 2.00 to 7.00. According to the industry distribution chart, Creative Medical Technology Holdings ranks #602 out of 1342 companies in the Biotechnology industry, placing it in the top 44.9%.
Is Creative Medical Technology Holdings' Piotroski F-Score too high?
Creative Medical Technology Holdings' current Piotroski F-Score of 3 is 25% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. The Biotechnology industry median Piotroski F-Score is 3.00. Creative Medical Technology Holdings' value of 3 is 0% at this industry median. Based on the distribution chart, Creative Medical Technology Holdings ranks #602 out of 1342 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Creative Medical Technology Holdings has a GF Scoreâ„¢ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Creative Medical Technology Holdings' Piotroski F-Score compare to APM and BCLI?
According to the Biotechnology industry distribution chart, Creative Medical Technology Holdings ranks #602 out of 1342 companies for Piotroski F-Score. This puts Creative Medical Technology Holdings in the upper half of its industry. The industry median Piotroski F-Score is 3.00. Creative Medical Technology Holdings' value of 3 is 0% at this benchmark. Historically, Creative Medical Technology Holdings' own Piotroski F-Score has ranged from 2.00 to 7.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 3.00, Creative Medical Technology Holdings has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,342 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Creative Medical Technology Holdings's current Piotroski F-Score of 3 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Creative Medical Technology Holdings and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creative Medical Technology Holdings's current Piotroski F-Score is 3, which is 25% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creative Medical Technology Holdings stock overvalued right now?
Based on GuruFocus' analysis, Creative Medical Technology Holdings (CELZ) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.32, compared to a current price of $2.00 — trading 525% above its estimated fair value. The current Piotroski F-Score is 3, which is 25% below median its 10-year median of 4.00 and 0% at the Biotechnology industry median of 3.00. Creative Medical Technology Holdings' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Creative Medical Technology Holdings (CELZ), the current Piotroski F-Score is 3 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Creative Medical Technology Holdings (CELZ) Overvalued in 2026?

Based on GuruFocus' analysis, Creative Medical Technology Holdings stock appears to be overvalued. The current stock price of $2.00 is trading 525% above its estimated GF Value™ of $0.32. GuruFocus considers Creative Medical Technology Holdings to be Significantly Overvalued.

Key valuation signals for CELZ:

  • Piotroski F-Score: 3 (25% below median its 10-year median of 4.00)
  • GF Value™: $0.32 vs. price of $2.00 (525% above fair value)
  • GF Score™: 36/100 with 4 warning signs
  • Industry Position: 0% at the Biotechnology median (#602 of 1342)

No single metric tells the full story. See the CELZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Creative Medical Technology Holdings Business Description

Address 211 E Osborn Road, Phoenix, AZ, USA, 85012
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
36GF Score

Get the complete analysis for CELZ

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.00
Price
$0.32
GF Value